Assess and address the lack of good quality clinical and health economic evidence using state of the art evidence generation methodologies
Provide a clear, engaging and strategic approach to communications with a wide range of stakeholders to address the poor awareness and understanding of rare conditions in the wider community
Effectively communicate the value of orphan and ultra orphan products to address the higher degree of uncertainty inherent to their evidence bases
120+
Abstracts
55+
Advisory boards/small meetings
45+
Congress-related activities
10+
Delphi Panels
100+
Design-related activities
165+
Education/Training Materials
125+
Manuscripts
10+
Oral presentations
125+
Poster presentations
15+
Lay summaries
15+
Strategic Publication Planning Support
10+
Virtual meeting/events
80+
Literature reviews [incl. critical appraisals and gap analyses]
120+
Economic Model Development and Validation
70+
HTA submissions
15+
Health Policy Projects
65+
Value Materials
25+
Statistical analyses
30+
RWE Projects
Our capabilities span primary and secondary research, including evidence generation strategy, real-world evidence studies, literature reviews, statistics and synthesis methodologies.
We can help you develop a compelling value proposition for your product, with rare disease expertise across market access, health technology assessments and health-economic modelling.
We are experts in planning and developing compelling communications, medical affairs and publications in rare diseases.
We are active contributors to rare disease industry initiatives and are regular partners with non-profits. Ongoing engagement enables us to deliver informed solutions for our clients and to provide expert support with policy activities.
Our Rare Diseases team recently conducted research, commissioned by the UK BioIndustry Associated (BIA) Rare Disease Industry Group, which estimated the socioeconomic burden of rare diseases in the UK.
Our article, recently published in the Guardian, explores the implications of the research findings for how we evaluate innovative medicines for rare diseases.
We are committed to actively contributing research and insights to overcome the challenges faced by industry and the rare disease patient community. Find out about some of our strategic solutions in our latest articles:
Our Rare Diseases team have recently published two pieces of internal research in leading Health Economics and Outcomes Research (HEOR) journals.
We’ve developed the first set of published recommendations on collecting clinical expert judgement in rare diseases.
We also conducted an SLR to review methods for generating utility data in rare diseases. The review highlights a need for appropriate disease-specific measures, and better reporting of vignette development.
